|1st January 2021||James F Young||10,000||Exercise of derivative||$0.00|
|31st December 2020||James F Young||1,000||Exercise of derivative||$50.00||$50,000.00|
|31st December 2020||James F Young||9,000||Open or private sale||$112.98||$1,016,824.50|
|31st December 2020||James F Young||2,000||Open or private sale||$113.60||$227,190.00|
|31st December 2020||Richard Douglas||1,000||Exercise of derivative||$50.00||$50,000.00|
|31st December 2020||James F Young||10,000||Exercise of derivative||$51.40||$514,000.00|
|28th December 2020||Rachel K. King||84,176||Open or private sale||$3.91||$329,128.16|
|28th December 2020||Rachel K. King||130,821||Exercise of derivative||$1.12||$146,519.52|
|16th December 2020||Michael A Jr Mcmanus||615||Grant/award etc.||$25.19||$15,491.85|
|1st October 2020||Stanley C Erck||2||Open or private sale||$108.57||$217.13|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Novavax, Inc. is a late-stage biotechnology company. It focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. Its vaccine candidates include ResVax and NanoFlu.